GlaxoSmithKline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Dividend

GlaxoSmithKline Pharmaceuticals recommended a final dividend of ₹57 per equity share for 2026. The record date is May 29, 2026, pending shareholder approval.

GlaxoSmithKline Pharmaceuticals Results Update

GSK India reported full-year revenue of ₹3790 Crore and PAT of ₹1012 Crore. The board recommended a final dividend of ₹57 per equity share.

Value

₹1,012 Cr

GlaxoSmithKline Pharmaceuticals Earnings Call: Key Takeaways

GSK India delivered a strong FY26 with 34.3% EBITDA margins and its first-ever PAT exceeding ₹1000 cr, driven by portfolio shifts toward high-growth Specialty and Innovative segments.

GlaxoSmithKline Pharmaceuticals Q4 FY26 Results: Net Profit ₹277.9 Cr, Up 5.7% YoY

GlaxoSmithKline Pharmaceuticals Ltd reported revenue from operations of ₹995.3 Cr (+2.1% YoY) and net profit of ₹277.9 Cr (+5.7% YoY) for Q4 FY26.

Key figure

Net profit ₹277.9 Cr · +5.7% YoY

GlaxoSmithKline Pharmaceuticals Financial Results

GSK Pharmaceuticals reported a consolidated net profit of ₹1,035.98 Crore for FY2026. The board also recommended a final dividend of Rs. 57 per share.

Value

₹1,036 Cr

GlaxoSmithKline Pharmaceuticals Board Meeting Outcome

GlaxoSmithKline Pharmaceuticals Limited has scheduled a board meeting on May 13, 2026. The board will consider audited standalone and consolidated financial results for the year ended March 31, 2026, and recommend a final dividend. The trading window remains closed until May 16, 2026.

GlaxoSmithKline Pharmaceuticals Board Meeting Outcome

GlaxoSmithKline Pharmaceuticals Limited has scheduled a Board Meeting on May 13, 2026. The directors will consider and approve the audited standalone and consolidated financial results for the year ended March 31, 2026. The board will also consider recommending a dividend on equity shares for the period.

GlaxoSmithKline Pharmaceuticals Other Announcement

GlaxoSmithKline Pharmaceuticals Ltd has authorized specific personnel, including the Managing Director and CFO, to determine the materiality of events for disclosure under SEBI Regulations. This administrative update ensures compliance with Regulation 30(5) regarding timely communication to stock exchanges.

GlaxoSmithKline Pharmaceuticals Management Change

GlaxoSmithKline Pharmaceuticals Limited appointed Mr. Vinay Subramanian as Commercial Head - Oncology, effective April 20, 2026. Mr. Subramanian brings 24 years of experience from Roche, GE Healthcare, and Pfizer. This leadership addition strengthens the company's oncology portfolio management and strategic business development in India.

GlaxoSmithKline Pharmaceuticals Management Change

GlaxoSmithKline Pharmaceuticals Limited has appointed Mr. Ronojit Biswas as an Executive Director for a three-year term starting April 1, 2026. A seasoned finance leader with over 25 years of global GSK experience, he previously served as CFO for GSK's Brazil and Vietnam operations.

Execution

36 months

GlaxoSmithKline Pharmaceuticals Management Change

GlaxoSmithKline Pharmaceuticals Ltd appointed Mr. Vinay Subramanian as Commercial Head – Oncology and Senior Management Personnel, effective April 20, 2026. Subramanian brings over 24 years of experience from Roche, GE Healthcare, and Pfizer. This leadership addition strengthens the company's oncology business segment and strategic management team in Mumbai.

GlaxoSmithKline Pharmaceuticals Annual General Meeting

GlaxoSmithKline Pharmaceuticals Ltd announced that shareholders approved the appointment of Mr. Ronojit Biswas as Director and Whole-time Director & CFO via postal ballot. The ordinary resolutions were passed with over 99.6% majority. This confirms leadership stability for the company's financial and administrative operations.